Skip to main content
. 2017 Sep 27;8(54):92454–92469. doi: 10.18632/oncotarget.21384

Figure 5. PLCE1 is aberrantly upregulated in ESCC and promotes tumorigenicity in vivo.

Figure 5

(A) Representative PLCE1 immunostaining in 98 samples of ESCC tissues and 32 samples of normal tissues. Original magnification is 200×. (B) Boxplot analysis of PLCE1 immunohistochemical scores in normal human esophageal squamous tissues and ESCC tissues (Student's t-test). (C) Mice transplanted with Eca109 shPLCE1 stable cells (n = 5) or Eca109/vector control cells (n = 5). The weight of mice were recorded at indicated times. (D) Image of representative tumors from control or shPLCE1-stable Eca109 xenografts obtained at the end point. (E) Xenograft tumor growth was monitored and showed as mean ± s.d (Student's t-test). (F) Tumor weights of mice harvested at 18 d after inoculation with Eca109/shPLCE1 cell lines (mean ± s.d., Student's t-test) compared with Eca109/vector cell lines. (G) An inverse relationship between miR-34a expression and PLCE1 protein level in ESCC tissues was established by Spearman correlation (r = -04685 with a significant P = 0.0189). (H) Immunohistochemical staining showing the differential expression of PLCE1 in ESCC with low or high miR-34a expression. * P < 0.05, ** P < 0.01, and *** P < 0.001.